Analysis Of Transfusion Dependence Development and Disease Evolution In Patients With MDS and Del(5q) and Without Transfusion Needs At Diagnosis

被引：0
|
作者：
Rojas, Silvia M.
Diez-Campelo, Maria
Luno, Elisa
Bernal, Teresa
Cabrero, Monica
Pedro, Carme
Calabuig, Marisa
Nomdedeu, Benet
Cedena, Teresa
Arrizabalaga, Beatriz
Garcia, Marta
Cervero, Carlos
Collado, Rosa
Azaceta, Gemma
Ardanaz, MarAa Teresa
Munoz, Juan A.
Xicoy, Blanca
Requena, Maria Jose
Bargay, Joan
Arilla, Maria Jesus
Amigo, Luz
Merchan, Brayan
Simiele, Adriana
Brunet, Salut
Gonzalez, Bernardo
Ramos, Fernando
Sole, Francesc
Consuelo, Del CaA'izo
机构：
来源：
BLOOD | 2013年 / 122卷 / 21期
关键词：
D O I：
10.1182/blood.V122.21.1542.1542
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
1542
引用
收藏
页数：2
相关论文
共 50 条
  • [41] CLINICAL BENEFIT OF LENALIDOMIDE TREATMENT FOR LOW AND INTERMEDIATE-1 IPSS RISK MYELODYSPLASTIC SYNDROME WITH DEL(5Q) BEFORE TRANSFUSION DEPENDENCE
    Oliva, E.
    Lauseker, M.
    Spiriti, M. A. Aloe
    Poloni, A.
    Cortelezzi, A.
    Palumbo, G.
    Balleari, E.
    Sanpaolo, G.
    Volpe, A.
    Ricco, A.
    Ronco, F.
    Alati, C.
    Santacaterina, I.
    Kuendgen, A.
    Germing, U.
    Latagliata, R.
    HAEMATOLOGICA, 2014, 99 : 517 - 517
  • [42] Phase 3 Study of Lenalidomide Vs Placebo in Non-Transfusion Dependent Low Risk MDS Del(5q) Patients: Preliminary Blinded Analysis of the European SINTRA-REV Trial
    不详
    CLINICAL ADVANCES IN HEMATOLOGY & ONCOLOGY, 2019, 17 (02) : 14 - 15
  • [43] RECURRENT MUTATIONS AS WELL AS CLONAL EVOLUTION ARE COMMON IN PATIENTS WITH LOWER-RISK MDS AND DEL(5Q) TREATED WITH LENALIDOMIDE
    Scharenberg, C.
    Karimi, M.
    Jansson, M.
    Walldin, G.
    Woll, P.
    Jacobsen, S. E.
    Hellstrom-Lindberg, E.
    LEUKEMIA RESEARCH, 2015, 39 : S84 - S84
  • [44] A PHASE 3 STUDY OF LENALIDOMIDE VERSUS PLACEBO IN RBC TRANSFUSION-DEPENDENT (TD) PATIENTS WITH LOWER-RISK MDS WITHOUT DEL(5Q) UNRESPONSIVE OR REFRACTORY TO ERYTHROPOIESIS-STIMULATING AGENTS (ESAS)
    Santini, V.
    Almeida, A.
    Giagounidis, A.
    Groepper, S.
    Jonasova, A.
    Vey, N.
    Mufti, G. J.
    Buckstein, R.
    Mittelman, M.
    Platzbecker, U.
    Shpilberg, O.
    Ram, R.
    del Canizo, C.
    Gattermann, N.
    Ozawa, K.
    Risueno, A.
    MacBeth, K. J.
    Zhong, J.
    Seguy, F.
    Hoenekopp, A.
    Beach, C. L.
    Fenaux, P.
    LEUKEMIA RESEARCH, 2015, 39 : S60 - S61
  • [45] Molecular characterization of deletions of the long arm of chromosome 5 (del(5q)) in 94 MDS/AML patients
    Douet-Guilbert, N.
    De Braekeleer, E.
    Basinko, A.
    Herry, A.
    Gueganic, N.
    Bovo, C.
    Trillet, K.
    Dos Santos, A.
    Le Bris, M. J.
    Morel, F.
    Eveillard, J. R.
    Berthou, C.
    De Braekeleer, M.
    LEUKEMIA, 2012, 26 (07) : 1695 - 1697
  • [46] Molecular characterization of deletions of the long arm of chromosome 5 (del(5q)) in 94 MDS/AML patients
    N Douet-Guilbert
    E De Braekeleer
    A Basinko
    A Herry
    N Gueganic
    C Bovo
    K Trillet
    A Dos Santos
    M J Le Bris
    F Morel
    J R Eveillard
    C Berthou
    M De Braekeleer
    Leukemia, 2012, 26 : 1695 - 1697
  • [47] A randomized study of lenalidomide (LEN) with or without EPO in RBC transfusion dependent (TD) IPSS low and int-1 (lower risk) myelodysplastic syndromes (MDS) without del 5q resistant to EPO.
    Toma, Andrea
    Chevret, Sylvie
    Kosmider, Olivier
    Delaunay, Jacques
    Stamatoullas, Aspasia
    Rose, Christian
    Beyne-Rauzy, Odile
    Banos, Anne
    Guercy-Bresler, Agnes
    Jourdan, Eric
    Sardnal, Veronique
    Caillot, Denis
    Laribi, Kamel
    De Renzis, Benoit
    Bordessoule, Dominique
    Slama, Borhane
    Sanhes, Laurence
    Fontenay, Michaela
    Fenaux, Pierre
    Dreyfus, Francois
    JOURNAL OF CLINICAL ONCOLOGY, 2013, 31 (15)
  • [48] Prospective cross-sectional analysis of cytopenias and transfusion needs of MDS patients in the USA
    Sekeres, M.
    Kantarjian, H.
    List, A.
    Lam, E.
    Leveque, J.
    Paquette, R.
    Maciejewski, J.
    LEUKEMIA RESEARCH, 2007, 31 : S108 - S109
  • [49] Survival, prognostic factors, and leukemic transformation in a multicenter study of 241 patients with MDS and del(5q)
    Germing, U.
    Hildebrandt, B.
    Symeonidis, A.
    Cermak, J.
    Pfeilstoecker, M.
    Noesslinger, T.
    Sekkeres, M.
    Maciejewski, J.
    Haase, D.
    Schlenk, R.
    Schanz, J.
    Seymour, J.
    Kenealy, M.
    Koeppler, H.
    Luebbert, M.
    Platzbecker, U.
    Valent, P.
    Blum, S.
    Ottmann, O.
    Goetze, K.
    Stauder, R.
    Kreuzer, K. A.
    Aul, C.
    Kuendgen, A.
    Giagounidis, A.
    LEUKEMIA RESEARCH, 2009, 33 : S74 - S74
  • [50] DEFINING LIKELIHOOD OF FUTURE RESPONSE IN PATIENTS WITH DEL(5Q) MYELODYSPLASTIC SYNDROMES (MDS) TREATED WITH LENALIDOMIDE
    Gerds, A. T.
    List, A. F.
    Giagounidis, A.
    Hellstrom-Lindberg, E.
    Li, J. Shiansong
    Swern, A. S.
    Sugrue, M. M.
    Fenaux, P.
    Sekeres, M. A.
    LEUKEMIA RESEARCH, 2015, 39 : S109 - S109
12345